What is your assessment of the cardiovascular risk profile associated with IL-6 therapy? And the possible role of IL-6 inhibition as a mitigator of any effects related to LDL elevation?

What is your assessment of the cardiovascular risk profile associated with IL-6 therapy? And the possible role of IL-6 inhibition as a mitigator of any effects related to LDL elevation?

What is your assessment of the cardiovascular risk profile associated with IL-6 therapy? And the possible role of IL-6 inhibition as a mitigator of any effects related to LDL elevation?


Created by

CMEducation Resources IQ&A Interactive Intelligence Zone

Presenter

Peter Nash, MD

Peter Nash, MD

Professor of Department of Medicine
Director of Rheumatology Unit on the Sunshine Coast
University of Queensland
Queensland, Australia